Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …

Background Abiraterone acetate plus prednisone significantly improved radiographic
progression-free survival compared with placebo plus prednisone in men with …

During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Background Androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs)
from patients with metastatic castration-resistant prostate cancer (mCRPC) was recently …

Purpose: The availability of newly approved treatment options for metastatic castration
resistant prostate cancer is not matched with conclusive data on optimal sequencing …